Literature DB >> 9163656

Rapid detection of multidrug-resistant tuberculosis.

M Goyal1, R J Shaw, D K Banerjee, R J Coker, B D Robertson, D B Young.   

Abstract

Transmission of multidrug-resistant strains of Mycobacterium tuberculosis (MDR-TB) presents a serious problem for infection control in hospitals, particularly in the context of co-infection with the human immunodeficiency virus (HIV). We report on the use of molecular genetic tools to allow rapid assessment of samples from patients potentially infected with MDR-TB. Sputum and bronchoalveolar lavage samples were obtained from two HIV-positive patients with suspected tuberculosis, who had previous contact with a known MDR-TB index case. Polymerase chain reaction (PCR) was used directly on clinical samples to amplify genetic loci associated with rifampicin resistance (rpoB), and strain-specific polymorphisms (the direct repeat (DR) region). Drug resistance was determined using a commercially available kit for detection of point mutations in the rpoB gene (Inno-Lipa RifTB; Innogenetics, Belgium), and confirmed by nucleotide sequencing. Strain variation was determined using the spoligotyping method, based on the presence or absence of variable linker sequences within the DR region. In one patient, infection with a MDR strain identical to that of a known index case was demonstrated. A second patient, although positive for M. tuberculosis, was found to be infected with a rifampicin-sensitive strain. Results were obtained within 48 h, allowing appropriate treatment to be initiated and infection control measures to be implemented. PCR-based tests for strain-typing and for identification of rifampicin resistance provide important tools for identifying patients with MDR-TB and for rapid monitoring of potential nosocomial spread of MDR-TB. Prompt confirmation or exclusion of possible transmission allows early clinical intervention to prevent future outbreaks of multidrug-resistant M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163656     DOI: 10.1183/09031936.97.10051120

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Evaluation of a PCR-based universal heteroduplex generator assay as a tool for rapid detection of multidrug-resistant Mycobacterium tuberculosis in Peru.

Authors:  Holger Mayta; Robert H Gilman; Fanny Arenas; Teresa Valencia; Luz Caviedes; Sonia H Montenegro; Eduardo Ticona; Jaime Ortiz; Rosa Chumpitaz; Carlton A Evans; Diana L Williams
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

3.  Genetic diversity among Mycobacterium bovis isolates: a preliminary study of strains from animal and human sources.

Authors:  M P Sales; G M Taylor; S Hughes; M Yates; G Hewinson; D B Young; R J Shaw
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

Review 4.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

5.  Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia.

Authors:  L K Yuen; D Leslie; P J Coloe
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

6.  Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda.

Authors:  Frank G J Cobelens; Einar Heldal; Michael E Kimerling; Carole D Mitnick; Laura J Podewils; Rajeswari Ramachandran; Hans L Rieder; Karin Weyer; Matteo Zignol
Journal:  PLoS Med       Date:  2008-07-08       Impact factor: 11.069

7.  Cost-effectiveness comparison of Genechip and conventional drug susceptibility test for detecting multidrug-resistant tuberculosis in China.

Authors:  Yu Pang; Qiang Li; Xichao Ou; Hojoon Sohn; Zhiying Zhang; Junchen Li; Hui Xia; Kai Man Kam; Richard J O'Brien; Junying Chi; Shitong Huan; Daniel P Chin; Yan-lin Zhao
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.